$CRVO
CervoMed Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Boston, MA
CRVO chart
What traders are saying about $CRVO
Latest postsCervoMed Inc. news
- CervoMed Says No Grant Revenue Recognized For Three Months Ended September 30, 2026
TradingView ·
- CervoMed Q3 net loss narrows as R&D costs drop after completion of RewinD-LB trial
TradingView ·
- CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Yahoo Finance ·
- CervoMed Inc reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- CervoMed Announces Q3 2026 Financial Results with 15.1 Million Shares Outstanding
Kalkine Media ·
- CervoMed 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary
TradingView ·
- With $19.6M in cash and securities, CervoMed (CRVO) warns it needs more funding.
Stock Titan ·
- Agenus (AGEN) Q3 Earnings Meet Estimates
Yahoo Finance ·
- CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Yahoo Finance ·
- CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Yahoo Finance ·
- CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Yahoo Finance ·
- CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Yahoo Finance ·
CervoMed Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 |
| Net income | -$27.0M | -$16.3M | -$2.2M | -$5.8M |
| Diluted EPS | – | – | – | $2038891.00 |
| Total assets (year end) | $22.9M | $43.1M | $10.0M | $4.2M |
| Cash and equivalents (year end) | $8.2M | $9.0M | $7.8M | $4.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About CervoMed Inc.
- Ticker
- CRVO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1053691
- Former names
- Diffusion Pharmaceuticals Inc., RestorGenex Corp, Stratus Media Group, Inc
Frequently asked questions
What exchange is CervoMed Inc. listed on?
CervoMed Inc. trades on the Nasdaq under the ticker symbol CRVO.
What industry is CervoMed Inc. in?
CervoMed Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is CervoMed Inc. headquartered?
CervoMed Inc.'s business address on file with the SEC is in Boston, MA.
When does CervoMed Inc.'s fiscal year end?
CervoMed Inc.'s fiscal year ends on December 31.
How much revenue did CervoMed Inc. report?
CervoMed Inc. reported $4.0M in revenue for calendar year 2025, according to its SEC filings.